

REVIEW ARTICLE | OPEN ACCESS

New therapeutic targets to prevent diastolic dysfunction in heart failure with preserved ejection fraction

Ying-Hsi Lin^{1,2}, Shuo Cong¹, Sang-Ging Ong^{3,4}, Chrishan J.A. Ramachandra^{1,2}, Derek J. Hausenloy^{1,2,4-7}

Heart failure with preserved ejection fraction (HFpEF) is poised to be the leading cause of heart failure in the near future. Currently, there are no specific therapies for improving morbidity and mortality associated with HFpEF and this has been attributed, in part, to its diverse etiology. One common feature, which defines HFpEF is diastolic dysfunction, a condition in which impaired left ventricular (LV) relaxation results in increased end-diastolic pressures and impaired blood filling. This manifests with signs and symptoms of congestive heart failure, despite LV systolic function being relatively preserved. Studies that have investigated the mechanisms underlying diastolic dysfunction have linked it to impaired cardiomyocyte relaxation and extracellular matrix (ECM)-related stiffening of the heart. Current treatment strategies for heart failure that target the sympathetic nervous system and the renin-angiotensin-aldosterone system have failed to improve prognosis in HFpEF. As such, there is an unmet need to identify new therapies that can directly ameliorate diastolic function and improve clinical outcomes in HFpEF. In order to achieve this, a comprehensive understanding of the multi-level processes that lead to diastolic dysfunction is required, which entail abnormal calcium handling, myofilament and cytoskeleton dysfunction, and abnormal ECM depositions. In this review article, we focus on the molecular mechanisms underpinning diastolic dysfunction, and also discuss potential therapeutic strategies for alleviating the impaired relaxation associated with HFpEF and improving clinical outcomes.

Keywords: Diastolic dysfunction, heart failure with preserved ejection fraction, myocardial stiffness, impaired relaxation, calcium handling, myofilament

Introduction

Cardiovascular disease (CVD) is the leading cause of death in the world and it has been estimated that more than 22.2 million people will die from CVD by 2030 (Virani et al., 2020). Among all the risk factors, heart failure (HF) has been the fastest-growing cause of CVD (Ziaeian et al., 2016) and accounted for 1 in 8 deaths in the U.S.A. in 2017 (<https://www.cdc.gov/>, 2019). Normal heart contractile function is critically dependent on a compliant left ventricle (LV) filling during diastole, and contraction of the LV in systole. HF occurs when the normal activity of the heart fails to pump enough blood to meet the demands of the body for oxygen and nutrient supply. Because of their mutual dependency, the impairment of either diastolic or systolic function can result in congestive HF. Based on the LV ejection fraction, HF is broadly divided into HF with reduced

ejection fraction (HFrEF, when LVEF is < 40%), HF with mid-range ejection fraction (when LVEF is 40-50%), and HF with preserved ejection fraction (HFpEF, when LVEF is > 50%) (Ponikowski et al., 2016; Yancy et al., 2017). Epidemiology studies have shown that HFpEF has morbidity and mortality that rivals HFrEF (Yancy et al., 2017). A variety of factors and comorbidities are associated with the development of HFpEF including advanced age, female sex, obesity, systemic arterial hypertension, diabetes mellitus, renal dysfunction, sleep disorders, and chronic obstructive pulmonary disease, conditions that result in systemic inflammation and endothelial dysfunction that may trigger adverse LV remodeling and result in HFpEF (Butler et al., 2014; Shah et al., 2016). Unlike HFrEF, for which there is a growing armamentarium of pharmacological agents with prognostic benefit, there are no specific therapies

¹National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore. ²Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore. ³Department of Pharmacology, University of Illinois College of Medicine, Chicago, Illinois, United States of America. ⁴Division of Cardiology, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois, United States of America. ⁵Yong Loo Lin School of Medicine, National University Singapore, Singapore. ⁶The Hatter Cardiovascular Institute, University College London, London, UK. ⁷Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan.

Correspondence should be addressed to Professor Derek J. Hausenloy (derek.hausenloy@duke-nus.edu.sg).

for improving clinical outcomes in patients with HFpEF. This likely relates to the latter's multi-factorial etiology, and an incomplete understanding of the pathophysiology underlying HFpEF. A key feature defining HFpEF is diastolic dysfunction, which is characterized by increased myocardial stiffness, impaired LV relaxation, increased LV end-diastolic pressures, and impaired LV filling, the clinical manifestations of which are congestive HF.

HFpEF was previously known as "diastolic HF (DHF)" a term referring to any clinical syndrome where congestive HF occurs in the presence of relatively normal LV systolic function. However, the term "diastolic HF" does not always equate to HFpEF, and this often generates confusion. Firstly, many HFrEF patients develop diastolic dysfunction, suggesting that diastolic dysfunction is not an exclusive feature of HFpEF (Aziz et al., 2013). Also, maintaining a normal ejection fraction does not necessarily mean that systolic function of HFpEF patients is normal. Other systolic parameters such as global longitudinal strain (GLS) have been shown to be compromised in HFpEF (Lekavich et al., 2015; Morris et al., 2014). Moreover, although diastolic function measurements remain the most heavily-weighted parameters according to the latest Heart Failure Association-Pretest Assessment (P), Diagnostic workup with echocardiogram and natriuretic peptide score (E), Advanced workup with functional testing in case of uncertainty (F), and Final etiological workup (F) (HFA-PEFF) diagnostic algorithm, an absence of diastolic dysfunction does not necessarily exclude the diagnosis of HFpEF (Pieske et al., 2019). Thus, the term "DHF" is much less commonly used nowadays since it does not describe the real scope of this syndrome. Nonetheless, the overall majority of HFpEF patients do have diastolic dysfunction despite the foregoing controversies, and there is no evidence supporting other more predominant contributors.

In order to improve HFpEF-related outcomes, a comprehensive understanding of the multi-level processes that lead to diastolic dysfunction is required. In this article, we review the molecular mechanisms (such as abnormal calcium handling, myofilament and cytoskeleton dysfunction, and abnormal extracellular matrix [ECM] depositions) underpinning diastolic dysfunction, and also discuss potential therapeutic strategies for alleviating the impaired relaxation associated with HFpEF for improved clinical outcomes.

Myocardial relaxation and passive LV stiffness as determinants of diastolic function

At the beginning of diastole, the ventricles relax and increase their volume with a rapid drop in intraventricular pressure. When the pressure is lower than atrial pressure, the atrioventricular valves open, allowing the majority of the blood to transit into the ventricles from the vena cavae and pulmonary veins (Fig. 1). Thus, the ventricles work as a "suction pump" during the early phase of blood filling (Robinson et al., 1986). After that, the subsequent atrial contraction pumps a relatively smaller volume of blood into the ventricles, which concludes diastole. Interestingly, since the heart does not have extensors unlike skeletal muscle, the driving force of behind ventricular relaxation in early diastole does not come from the work of contractile units. Instead, it is the recoiling movement powered from the elastic elements of the heart, such as elastin and collagen of the extracellular matrix (ECM), titin of cardiomyocytes, and even pericardium. During systole when the chambers contract against arterial load, it simultaneously compresses these elements, storing the elastic energy, much like a compressed spring. When electrical excitation is over, the contractile units of the cardiomyocytes stop generating force, the stored energy releases and powers the whole chamber to recoil back to the original position.

Two key determinants of myocardial relaxation are

cardiomyocyte contractile mechanisms and passive stiffness of the LV. Cardiomyocyte relaxation is an energy-consuming process, mediated by the calcium (Ca^{2+}) handling system and the basic relaxation properties of the myofibrils. The Ca^{2+} handling system controls how fast intracellular Ca^{2+} is removed from the cytoplasm and is mainly governed by the sarcoplasmic reticulum Ca^{2+} ATPase pump (SERCA) (Maruyama et al., 1989). Also, the relaxation of myofibrils requires the binding of ATP to proceed (Poggesi et al., 2005; Weber et al., 1973). Passive stiffness of the myocardium relates to LV compliance and is strongly influenced by changes in the composition of ECM (e.g. interstitial fibrosis), and modulation of myofibrillar proteins (e.g. Titin) and cytoskeleton components. Fig. 2 summarizes the complexity of the regulatory processes that impact on diastolic function. This complexity possibly explains why HFpEF is such a heterogeneous syndrome as any molecular and cellular alterations on different biological levels could compromise diastolic function. In the following sections, we will focus on how these alterations impact on myocardial relaxation and passive stiffness, and highlight potential new targets for ameliorating diastolic dysfunction in HFpEF.

Calcium dysregulation and impaired cardiomyocyte relaxation

Calcium (Ca^{2+}) handling plays a central role as a mediator of contraction and relaxation of cardiomyocytes. The sarcoplasmic reticulum (SR) is a subcellular membrane network that stores the majority of Ca^{2+} in cardiomyocytes. Contraction of cardiomyocytes relies on a process termed calcium-induced calcium release (CICR) in which the action potential stimulates Ca^{2+} influx from L-type Ca^{2+} channel, which opens the ryanodine receptor (RyR), followed by Ca^{2+} release from SR through the RyR to activate myofibrils (Bers 2002; Fabiato et al., 1979). After electrical stimulation, the relaxation of cardiomyocytes requires removal of Ca^{2+} from the cytosol to deactivate the myofibrils and this is mainly mediated via SERCA. The cardiac-specific isoform SERCA2a is an integral SR membrane protein that has a high affinity for Ca^{2+} on the cytosolic side, and transports Ca^{2+} to the lumen side of the SR with the consumption of ATP, essentially functioning as a Ca^{2+} pump (Fig. 2). The activity of SERCA2a is regulated by two smaller integral SR membrane proteins: phospholamban (PLN) and sarcolipin (SLN). Phospholamban serves as a SERCA2a inhibitor by interacting with SERCA2a and decreasing its affinity for Ca^{2+} (Akin et al., 2013; MacLennan et al., 2003). The activity of PLN is regulated by its phosphorylation at Ser16 and/or Thr17, which promotes the oligomerization of PLN and releases its inhibition on SERCA2a (Ablorh et al., 2015; Tada et al., 1996). SLN is structurally similar to PLN and also inhibits SERCA2a function (Bhupathy et al., 2007), but acts more like an uncoupler between Ca^{2+} transport and ATP hydrolyzation (Shaikh et al., 2016).

Even though SERCA2a function has been linked to myocardial relaxation, most studies have investigated the role of impaired SERCA2a function in systolic HF (Hasenfuss et al., 1993; Houser et al., 2000; Morgan 1991). This is not surprising since SERCA2a not only plays a central role in Ca^{2+} removal for cardiomyocytes to relax, but also the availability of Ca^{2+} to activate myofibrils. Impaired SERCA2a activity can be either transcriptional or post-translational. Gene expression of SERCA2a has been shown to be down-regulated in end-stage failing hearts (Arai et al., 1993; Eisner et al., 2013). Also, the chronic sympathetic nervous system in HF can desensitize β -adrenergic signaling, the downstream effect of which is reduced PLN phosphorylation that inhibits SERCA2a (Marks 2013; Schmidt et al., 1999). SERCA2a is also a direct target of oxidative modification by increased reactive oxygen species (ROS) (Balderas-Villalobos et al., 2013; Viner et al., 1999;




Figure 1. Wiggers diagram and cardiac cycle. (1) Isovolumetric contraction: closure of atrioventricular (AV) valves with rapid rise of intraventricular pressure without volume change; (2) Ejection: intraventricular pressure surpasses aortic pressure and opens aortic valves. Rapid blood outflow from the ventricle to aorta followed by slowing down of outflow because of the turning-off of contractile units; (3) Isovolumetric relaxation: intraventricular pressure becomes lower than aortic pressure. AV valves close with rapid decrease in intraventricular pressure without volume change; (4) Atrial filling: start of blood filling into atrial with AV valves closed; (5) Intraventricular pressure becomes lower than atrial pressure. AV valves open and blood filling into the ventricle (E or early wave); (6) Ending of diastole with atrial contraction to eject smaller amount of blood into the ventricle (A or atrial wave).

Zima et al., 2006), which commonly occurs in acute myocardial ischemia-reperfusion injury or diabetic HF with impaired mitochondrial function (Zarain-Herzberg et al., 2014).

Overexpression of SERCA2a has been shown to be beneficial in HFrEF (Baker et al., 1998; Del Monte et al., 1999), and it has been demonstrated that diastolic function can also be improved by increasing SERCA2a function (Baker et al., 1998; Iwanaga et al., 2004). Several groups are now focusing on the role of SERCA2a in HFpEF. Groban et al. (2012) first reported that diastolic function was improved along with reduced PLN/SERCA2a ratio when aging rats were treated with angiotensin converting enzyme inhibitor (ACE-I). This finding is consistent with later reports showing reduced SERCA2a activity in hypertensive animal models of diastolic dysfunction with preserved ejection fraction (Rouhana et al., 2019; Tanaka et al., 2014). Furthermore, anti-oxidative agents have been shown to benefit diastolic dysfunction with a potential link to restored SERCA2a function (Scotcher et al., 2016; Wilder et al., 2015), but the mechanisms are unclear.

The sodium-calcium exchanger (NCX) is another mediator of Ca^{2+} removal during cardiomyocyte relaxation, but only makes a small contribution (Bassani et al., 1994; Pieske et al., 1999). NCX is a plasma membrane integral protein that uses the electrochemical gradient of sodium (Na^+) to drive one Ca^{2+} ion out of the cell in exchange for 3 Na^+ ions (Bers 2002). The expression of NCX is usually increased in animal models of HFrEF (Bers et al., 2010), although the findings in human HFrEF are more inconsistent (Hasenfuss et al., 2002). The overall contribution of NCX for Ca^{2+} removal is increased because of reduced SERCA activity (Piacentino III et al., 2003). NCX appears to act differently in HFpEF. In the hypertensive animal, Rouhana et al. (2019) established that NCX activity is decreased along with SERCA2a, suggesting it might be another contributor to elevated diastolic $[\text{Ca}^{2+}]_i$, which potentially leads to relaxation impairment. In some end-stage HFrEF hearts, the activity of NCX is limited because extra Na^+ efflux results in

reversed Ca^{2+} extrusion, which does not happen in HFpEF (Nuss et al., 1992).

Therapeutic targeting of SERCA2a in HFpEF

Given the beneficial roles of SERCA2a in both systolic and diastolic function in animal models, clinical trials have tested the upregulation of SERCA2a as a therapeutic strategy for HF. The “Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)” trial demonstrated that adeno-associated virus serotype 1-delivered SERCA2a gene (AAV1/SERCA2a) therapy in HFrEF patients reduced the rate of re-hospitalization for HF (Hajjar et al., 2008; Jaski et al., 2009). Despite these promising results, the follow-up larger phase 2b CUPID2 trial failed to show any benefit (Fernández-Ruiz 2016; Greenberg 2017). The failure of SERCA2a gene therapy has been attributed to the potential effects of B-type natriuretic peptide (BNP) on SERCA2a expression (Zhai et al., 2018), and it has been suggested that SERCA2a gene therapy may be beneficial in HFpEF where BNP levels tend to be lower than in HFrEF. The funny (I_f) channel inhibitor, ivabradine, has been reported in a small clinical trial of 61 patients to improve exercise capacity, LV filling pressures, and diastolic function of HFpEF patients (Kosmala et al., 2013). Although the main action of ivabradine is to reduce heart rate, it is also known to be a SERCA2a activator (Reil et al., 2013; Xie et al., 2020), supporting a beneficial role of SERCA2a in HFpEF. However, the larger “Preserved Left Ventricular Ejection Fraction Chronic Heart Failure With Ivabradine Study (EDIFY)” trial failed to demonstrate improved diastolic function with ivabradine in HFpEF patients (Komajda et al., 2017). Istaroxime is another activator of SERCA2a that acts by blocking the SERCA2a–PLN interaction (Huang 2013). It has been tested in the Hemodynamic Effects of Istaroxime in Patients with Worsening HF and Reduced LV Systolic Function (HORIZON-HF) trial in HFrEF patients (Shah et al., 2009), and was shown to lower pulmonary capillary wedge pressure (PCWP) and improve

diastolic function, effects that might benefit HFpEF. A clinical trial with this agent is currently ongoing in HFpEF patients (clinicaltrials.gov, NCT02772068).

Myofilament dysfunction and impaired cardiomyocyte relaxation

Myofibrils are the most abundant organelle and are the basic contractile unit of the cardiomyocytes (Gerdes 2012). Contraction and relaxation are mediated by alternating sliding actions between the thin and thick filaments toward or away from the M-band (Huxley 1957). The thin filament is composed of filamentous sarcomeric α -actin with regulatory proteins troponin complex (Tn) and tropomyosin (Tm). The thick filament consists of myosin heavy chains (MHC), regulatory myosin light chains (RLC), essential myosin light chain (ELC), and myosin binding protein C (MyBP-C). The protruding globular region of MHC, termed cross-bridge, can interact with actin using ATP to generate force to pull the thin filament towards the center of the sarcomere (Weber et al., 1973). Myofibril function is tightly coupled with intracellular Ca^{2+} signaling. During contraction, elevated $[Ca^{2+}]$ from SR propels Ca^{2+} to bind to TnC. This results in conformational changes in the troponin complex and releases the allosteric inhibition of Tm, allowing the cross-bridges to interact with actin and generate force (Fig. 2). During relaxation, Ca^{2+} is removed by SERCA2a and NCX, the interaction of cross-bridges to actin arrests, thereby allowing the sarcomere to slide back into the relaxed state (Ebashi et al., 1968; Gordon et al., 2000; Lin et al., 2019).

At the myofibril level, cardiomyocyte relaxation can be modulated via two distinct pathways, Ca^{2+} sensitivity and relaxation properties of the myofibril itself. Ca^{2+} sensitivity refers to how readily the myofibrils are activated by Ca^{2+} . During cardiomyocyte relaxation, Ca^{2+} sensitivity of the myofibrils determines the rate of relaxation of the myofibrils. As for myofibril relaxation, it is important to appreciate the distinction between “relaxation of cardiomyocytes” and “relaxation of myofibrils.” The inactivation of myofibrils begins when dissociation of Ca^{2+} turns off cross-bridges. The pure relaxation kinetics of the myofibrils after Ca^{2+} removal has a unique “bi-phasic” pattern – linear phase and exponential phase of relaxation (Stehle et al., 2002; Tesi et al., 2002), a finding which is not observed in cardiomyocyte relaxation. The reason for this is that cell relaxation is the combination of Ca^{2+} handling and myofibril relaxation processes, and the fall of cytosolic $[Ca^{2+}]$ is a much more gradual process than myofibrils (Backx et al., 1995; Blinks et al., 1978). In many cases, alterations in general myofibril relaxation kinetics can translate to the whole-cell level as several recent studies have demonstrated (Coppini et al., 2017; Jeong et al., 2018; Lin et al., 2020). However, the different phases of relaxation from the myofibril study can provide further insights into the potential molecular basis of these abnormalities. For example, the investigation of the impaired linear phase relaxation should focus on how the thin filament is inactivated by the action of the Tn complex, whereas the impaired exponential phase of relaxation is more relevant to the cross-bridge cycling between the thin and thick filaments and the elastic properties of the myofibrils provided by titin (Lin et al., 2019; Stehle et al., 2009). Titin is the third major structure of the myofibrils. In contrast to the thin and thick filaments, titin does not have a contractile function but is the main player that mediates passive stiffness of the myofibrils (Granzier et al., 2002). Alterations of sarcomere proteins can directly affect stiffness and relaxation of the cardiomyocytes and potentially result in HFpEF.

Therapeutic targeting of titin in HFpEF

Titin is the largest human protein (35,000 amino acids in

length), as evidenced by the length of one single titin molecule spanning from the Z disc to the central M line. Titin provides structural support and elasticity of the myofibrils, a property that can directly translate to passive stiffness at the whole heart level (Chung et al., 2011). Because of its extreme length, titin comprises many different structural elements (LeWinter et al., 2010), and goes through a series of alternative splicing during development (Guo et al., 2010). The shorter and stiffer N2B isoform is the predominant isoform in the mature human heart in contrast to the longer and more compliant N2BA isoform (Warren et al., 2004). Another determinant of titin stiffness are post-translational modifications (PTMs) of amino acids located in its key structural elements, many of which have been characterized: (1) Decreased stiffness by phosphorylation at Ser4010 and/or Ser4099 of the N2B unique sequence (N2Bus) by protein kinase A and G (PKA and PKG) (Borbély et al., 2009; Krüger et al., 2009); (2) Increased stiffness by phosphorylation at Ser11878 and/or Ser12022 of the PEVK (Pro-Glu-Val-Lys) domain by protein kinase C alpha (PKC α) (Hidalgo et al., 2009); (3) Increased stiffness by disulfide bond formation at 6 cysteine residues in N2Bus (Grützner et al., 2009); and (4) Decreased stiffness by S-glutathionylation at the cryptic cysteines located in immunoglobulin (Ig) domains (Alegre-Cebollada et al., 2014).

The ratio of N2B/N2BA isoforms has long been shown to be altered in pathological conditions in response to stress (Neagoe et al., 2002; Wu et al., 2002). In 2006, van Heerebeek et al. (2006) compared the stiffness and N2B/N2BA ratio between heart tissues from HFREF and HFpEF patients and found HFpEF patients had higher N2B expression than HFREF patients, but it was later found that N2B/N2BA ratio is unchanged when HFpEF hearts are compared to non-failing hearts (Hopf et al., 2018; Zile et al., 2015). Instead, Hamdani et al. (2013) used a mouse HFpEF model stimulated by a combination of metabolic dysfunction and high fat diet, and found the N2Bus region of titin to be hypophosphorylated, which was accompanied by diastolic dysfunction and increased titin stiffness, and this could be ameliorated by activated PKG signaling (Hamdani et al., 2014). These results were confirmed by Zile et al. (2015) using heart tissues from HFpEF patients. The nitric oxide (NO)/cyclic GMP/PKG pathway is known to be impaired with increased oxidative stress (Kasner et al., 2011; Park et al., 2018), likely explaining why increased stiffness is the signature feature of HFpEF observed in diabetic cardiomyopathy (van Heerebeek et al., 2009). In contrast, reports from phosphorylation in the PEVK region of titin in HFpEF hearts have been inconsistent (Hamdani et al., 2013; Hopf et al., 2018).

Other strategies that have been tested in the experimental setting to reduce titin stiffness include: (1) exercise, which was shown to reduce titin stiffness and improve diastolic function in a mouse model of HFpEF (Slater et al., 2017), although the mechanism was not addressed; (2) Metformin, a commonly used diabetic drug, was shown to reduce titin stiffness and improve diastolic function via PKA phosphorylation in the N2Bus region of titin (Slater et al., 2019). This result is consistent with an earlier study using another antidiabetic drug empagliflozin (SGLT2 inhibitor) on ventricular trabeculae from HF patients although no explanation for the underlying mechanism was provided (Pabel et al., 2018). However, one can speculate that amelioration of metabolic dysfunction is beneficial to titin stiffness-regulated diastolic function; and (3) RNA binding motif 20 (RBM20), the known regulator that switches titin isoforms by alternative splicing to the stiffer N2B isoform has been investigated as a therapeutic target for improving diastolic function (Guo et al., 2012). In animal studies, cardiac-specific RBM20 knockout mice were shown to have much more compliant myofibrils, ventricle chamber, and improved diastolic function in response to HFpEF (Methawasin




Figure 2. Determinants of myocardium relaxation. Diastolic function of the heart is governed by the stiffness of the myocardium as well as the relaxation action of the contractile unit. Extracellular regulation (top panel): the composition of extracellular matrix mediates the stiffness of the non-contractile elements of the myocardium. Amyloidosis is another extracellular cause of myocardial stiffening. Intracellular regulation (lower panel): muscle relaxation property is mediated by the calcium handling system of the cardiomyocyte or the basic contractile/relaxation properties of the myofibrils. Stiffness of cardiomyocyte is mainly mediated by giant protein titin.

et al., 2016). Based on the promising experimental results showing that PKG phosphorylation of the titin N2Bus region could improve diastolic dysfunction, the RELAX trial was performed using the phosphodiesterase 5 inhibitor, sildenafil, which can enhance PKG activity, but six months treatment with sildenafil did not improve exercise capacity or clinical status (Redfield et al., 2013). The above new findings shed light on using titin as a potential therapeutic target to improve the compliancy of the HFpEF heart despite earlier failure of the RELAX trial.

Alterations in myofibril mechanics and impaired cardiomyocyte relaxation

The cardiac troponin complex (cTn) directly regulates the response of the thin filament to Ca^{2+} and impacts on myofibril relaxation (Gordon et al., 2000). Failure to efficiently turn off cTn leads to enhanced Ca^{2+} sensitivity and prolonged relaxation (Chung et al., 2016). Thus, it is not surprising that the inhibitory cardiac troponin I subunit (cTnI) was among the earliest proteins identified in inherited restrictive cardiomyopathies (RCM) (Gomes et al., 2005; Mogensen et al., 2003), the class of cardiomyopathy known to result from relaxation impairment without showing systolic dysfunction. cTnI mutations can be also seen in some hypertrophic cardiomyopathy (HCM) patients, whose pathological phenotypes sometimes show prolonged relaxation as well. In HCM and RCM heart tissues, Ca^{2+} sensitivity is generally elevated accompanied by prolonged myofibril relaxation kinetics (Cheng et al., 2015; Iorga et

al., 2008; Kruger et al., 2005), with occasional exceptions (Dvornikov et al., 2016). cTnI can be phosphorylated by several protein kinases (Solaro et al., 2013), the most well-known of which is PKA. PKA-phosphorylated cTnI reduces Ca^{2+} sensitivity and is beneficial for relaxation (Cheng et al., 2015; Zhang et al., 1995). Recently, Lin et al. (2020) reported that acetylation-mimic mutations in the actin-binding region of cTnI leads to reduced Ca^{2+} sensitivity and faster relaxation at both the cellular and myofibril levels in a PKA-independent manner, but the effect on the whole heart was not addressed.

In addition to the regulatory system of the thin filament, the kinetics of force-generating myosin cross-bridges can also modulate Ca^{2+} sensitivity and myofibril relaxation (Robinson et al., 2002). Myosin RLC and ELC are a pair of myosin light chains located in the neck of the myosin head. In two RCM models, mutations in RLC and ELC increased Ca^{2+} sensitivity and diastolic dysfunction of the heart (Abraham et al., 2009; Yuan et al., 2017). Also, phosphorylation of RLC results in increased Ca^{2+} sensitivity and delayed relaxation (Colson et al., 2010; Sevrieva et al., 2020). Cardiac specific MyBP-C3 is a thick filament-associated protein that controls the interactions between the myosin S2 domain and α -actin. Ablation of MyBP-C3 has been shown to result in increased Ca^{2+} sensitivity and faster relaxation because of accelerated cross-bridge kinetics (Moss et al., 2015). Phosphorylation of MyBP-C3 also speeds up relaxation, which alleviates diastolic dysfunction in an aging mouse model (Rosas et al., 2015; Rosas et al., 2019). Despite these interesting results showing that the thick

filament proteins could be closely linked to muscle relaxation and diastolic dysfunction, detailed myofibril mechanics of these alterations are still not fully understood and need further investigation.

Therapeutic targeting of the contractile apparatus to improve myofibril relaxation in HFpEF

A number of pharmacologic interventions for improving maladaptive contractile function of the myofibrils in HFpEF have been investigated (Bristow 2000; McMurray et al., 2014; Teerlink et al., 2016). There are several challenges associated with targeting myofibrils to improve diastolic function in HFpEF. The onset of HFpEF, which mainly results from reduced contractility, can be targeted by pharmacological agents to either improve contractility of the myofibrils or decrease the afterload of the heart. In contrast, HFpEF is more complex and is characterized by passive stiffening and impaired cardiomyocyte relaxation. Furthermore, the mechanisms underlying the relaxation impairment of the myofibrils is difficult to dissect from disturbed calcium handling at the level of cardiomyocyte.

With advances in cellular or *ex vivo* myofibril mechanics system, it is now possible to decipher the contribution of myofibril mechanics to the development of diastolic dysfunction in HFpEF. Jeong et al. (2018) have investigated myofibril mechanics of explanted LV tissue from two patients diagnosed as idiopathic RCM with symptoms of HFpEF. They found prolonged myofibril relaxation compared to control donors as seen in two small animal models of diastolic dysfunction and preserved EF. Interestingly, the diastolic dysfunction as well as myofibril relaxation were improved by the pan-histone deacetylase (HDAC) inhibitor givinostat (Jeong et al., 2018). This was the first evidence showing that relaxation at the myofibril level could be improved by a pharmacological intervention. Recently, Wallner et al. (2020) treated a feline model of HFpEF with another pan-HDAC inhibitor, suberoylanilide hydroxamic acid, and observed similar results. With the advancement of techniques, it is now feasible to assess the mechanical properties of myofibrils from cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) (Pioner et al., 2020; Pioner et al., 2016) or living human heart tissue culture (Ou et al., 2019). Whether human myofibrils with relaxation impairment in HFpEF patients can be corrected by HDAC inhibition remains to be determined. A recent publication from Wu et al. (2019) assessed three different hiPSC-derived cardiomyocytes (CM) from inherited diastolic HF patients with myofibrillar protein mutations, and found enhanced Ca^{2+} sensitivity and slower relaxation in all of them. Despite no direct mechanism for their finding, this shows iPSC-CMs could be an ideal tool for drug screening in the near future.

The cytoskeleton and cardiomyocyte relaxation

Microtubule and intermediate filament desmin

A microtubule (MT) is composed of α/β tubulin heterodimers that polymerize to form a hollow tubes-shaped cytoskeleton about 25 nm in diameter (Stephens et al., 1976). The role of MTs in cardiomyocytes and how they mediate mechanical function has been overshadowed by the myofilament system for years. In 2016, it was unveiled by the Prosser Lab that MTs can mechanically couple to the sarcomere and provide resistance, acting like a spring that deforms into sinusoidal buckles during cardiomyocyte contraction (Robison et al., 2016). This “buckling” action requires the detyrosination (dTyr) of α -tubulin and the presence of intermediate filament desmin. Down-regulation of dTyr or desmin substantially reduced stiffness of the entire cardiomyocyte (Granzier et al., 1995). Follow-up studies from the same group demonstrated that

detyrosination of MTs is increased in human cardiomyocytes isolated from HFpEF patients and can be relieved by adenoviral overexpression of tubulin tyrosine ligase (TTL) or the knock-down of a newly identified α -tubulin detyrosinase vasohibin-small vasohibin binding protein (Caporizzo et al., 2020; Chen et al., 2018; Chen et al., 2020). However, there are two issues that need to be addressed before MT-based stiffness correction can be considered a therapeutic option: (1) Despite promising data from human cardiomyocytes, it remains to be shown whether detyrosination of the MTs can be demonstrated in an *in vivo* system; (2) Pharmacological agents that can specifically target detyrosination at the level of MTs are needed. Nonetheless, the breakthrough finding of MT-regulated cardiomyocyte stiffness has offered a novel therapeutic target for the treatment of HFpEF.

Filamin C

Filamins are a family of large cytoskeletal proteins that organize filamentous actin (f-actin) into networks and also anchor various plasma membrane integral proteins to the actin cytoskeleton to provide a scaffold for a variety of cytoplasmic signaling pathways (Stossel et al., 2001). Filamin C is the muscle-specific filamin that modulates actin dynamics and plays an important role in myofibrillogenesis (Chiang et al., 2000). Filamin C deficiency in mice is lethal at birth due to underdeveloped skeletal muscles and respiratory system failure (Dalkilic et al., 2006). In matured cardiomyocytes, filamin C acts as a signaling hub to repair damaged myofibrils (Leber et al., 2016). Filamin C has high expression in the heart and is one of the major non-myofibrillar proteins that could result in cardiomyopathies. Recently, it was found that missense mutations of filamin C leads to RCM and HCM (Brodehl et al., 2016; Gómez et al., 2017), which tend to develop diastolic dysfunction and HFpEF (Seferović et al., 2019). The mechanism through which abnormal filamin C causes these phenotypes is unclear. However, histological staining of RCM heart tissue from filamin C mutation showed cytoplasmic aggregates formed by mutant filamin (Brodehl et al., 2016). The authors speculated that protein aggregates could increase cellular stiffness and relaxation properties (Plodinec et al., 2011), which may explain the restrictive phenotype. Further identification of the molecular causes underlying HCM/RCM is required to get a better understanding for gene-specific diagnosis and potential therapy.

Extracellular matrix and stiffening of the myocardium

Myocardial fibrosis in HFpEF

Fibrosis is defined as the abnormal deposition of ECM in tissues via a cascade of cellular responses to injuries. It commonly begins as an adaptive response but ultimately progresses into cellular dysfunction (Rockey et al., 2015). Myocardial fibrosis is the hallmark of detrimental adaptation of the heart that likely progresses to HF. It is a well-known feature of HFpEF after myocardial infarction and results from replacement of dead cardiomyocytes, which eventually contributes to systolic dysfunction because of impaired myocardial force transduction or increased workload of the remaining cardiomyocytes (Baicu et al., 2003; Heineke et al., 2006). HFpEF has been previously reported to have a similar collagen level as HFpEF (Borbély et al., 2005; van Heerebeek et al., 2006). Since one of the features of abnormal ECM deposition during fibrosis is increased stiffness of organs including the heart (Norton et al., 1997; Yamamoto et al., 2002), it was frequently speculated that a stiffened myocardium is the cause of diastolic dysfunction in HFpEF. The major cause of myocardial fibrosis of HFpEF is the inflammatory responses driven by comorbidities such as hypertension, coronary microvascular disease, or metabolic dysfunction (Friebel et al., 2019; Glezeva et al., 2014; Paulus

et al., 2013). For example, chronic hypertension commonly leads to endothelial damage and vascular inflammation, thereby triggering the differentiation of circulating monocytes into macrophages, which secretes pro-fibrotic factors such as transforming growth factor- β (TGF- β), and eventually leads to fibrosis (Mouton et al., 2020). Some studies reported the elevated stiffness induced by fibrosis was directly linked to diastolic dysfunction in animal HFpEF models (Cieslik et al., 2011; Martos et al., 2007) and HFpEF patients (Rommel et al., 2016; Su et al., 2014). Recently, HFpEF has been shown to have more collagen volume than HFrEF (Dai et al., 2012; Echegaray et al., 2017), and a different spectrum of ECM composition that results in higher stiffness (Bielecka-Dabrowa et al., 2016; Kasner et al., 2011). This could explain why the myocardium of HFpEF typically has higher stiffness than HFrEF and worse diastolic function (Aziz et al., 2013; Røe et al., 2017).

Amyloidosis is a common disease in the elderly that occurs when insoluble misfolded proteins deposit in tissues and organs (Dubrey et al., 2011). Amyloidosis is different from fibrosis as the origin of amyloid is from proteins arranged into a fibril like structure instead of ECM. In the heart, amyloidosis results in stiffening of the heart chamber, which results in diastolic dysfunction (Bhupathi et al., 2011; Pislaru et al., 2019), and is frequently present (5-13%) in patients diagnosed with HFpEF (González-López et al., 2015). There are several types of amyloidosis derived from different proteins such as immunoglobulin light and heavy chain (AL and AH) or transthyretin (ATTR) triggered from totally different etiologies (Kholova et al., 2005). Hearts with amyloidosis might have higher fibrosis, which is likely linked to inflammatory responses (Buxbaum et al., 2012; Mohammed et al., 2014), but they do not seem to have a direct correlation.

Therapeutic targeting of fibrosis to improve myocardial relaxation

The common end point of myocardial fibrosis is the activation of cardiac fibroblasts when TGF- β binds to its receptor and initiates signaling pathways (Bujak et al., 2007). This leads to the nuclear import of Smad2/3 to prime pro-fibrotic genes (Khalil et al., 2017). The activation of fibroblasts plays pivotal roles in the secretion of major ECM materials such as collagen, fibrin, fibronectin, proteoglycans, and glycosaminoglycans (Tracy et al., 2016). The anti-fibrotic compound, pirfenidone, blocks the transport of Smad2/3 by inhibiting p38- γ (Dosanjh 2007) and has been shown to ameliorate myocardium fibrosis in two rodent models of diastolic dysfunction (Miric et al., 2001; Mirkovic et al., 2002). In HFpEF, the clinical trial “PIROUETTE (Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction)” is ongoing to test the efficacy and safety of pirfenidone to treat HFpEF patients with evidence of myocardial fibrosis (clinicaltrials.gov, NCT02932566). Advanced glycation endproducts (AGE) are the products of glycated proteins or lipids that can crosslink and act as another major determinant of the stiffness of ECM (Hartog et al., 2007). Increased AGE crosslinking has been found in HFpEF patients (Kasner et al., 2011; Willemsen et al., 2012). Several studies in diabetic animal models have shown improvement of diastolic function when AGE crosslinking is blunted (Kranstuber et al., 2012; Ma et al., 2009). Earlier in 2005, a small, open-label trial also showed an AGE crosslinking breaker, ALT-711, improved diastolic function in aging patients (Little et al., 2005), suggesting a potential approach for treatment. In general, fibrosis exists in virtually all organs in the body with complex dynamics and large numbers of players, thus, it is challenging to focus on specific pathways to treat fibrosis. Recently, high throughput screening for synthetic or natural compounds has been applied to search for more potent therapeutics for cardiac fibrosis

(Palano et al., 2020; Schimmel et al., 2020). However, there is still a void between basic science and clinical application in most studies to date.

Future perspective and conclusion

Among all HF patients, approximately 50% of them are diagnosed to have HFpEF (Dunlay et al., 2017). Furthermore, the prevalence of HFpEF relative to HFrEF is increasing with the majority being > 65 years old (Gerber et al., 2015; Steinberg et al., 2012). With the increasing trend of an aging population, HFpEF is projected to be the most common form of HF (Ambrosy et al., 2014). Unfortunately, despite abundant research efforts on HFpEF, its morbidity and mortality are still rising (Ponikowski et al., 2016; Yancy et al., 2017) without pharmacological therapy showing similar benefits as in HFrEF (Ponikowski et al., 2016; Roh et al., 2017). This is most likely due to the multifactorial pathophysiology that involves not only diastolic dysfunction but also perturbations in non-cardiac factors such as pulmonary and systemic vascular systems and renal function (Lam et al., 2018). This heterogeneity is not surprising given the definition of HFpEF comes from the mix of HF patients that do not have a single symptom (reduced EF). Thus, HFpEF can essentially be regarded as many different diseases based on this notion.

Despite the heterogeneity of HFpEF, it is possible to extrapolate common features of HFpEF and assess how they are initiated in response to the pathological stimulus. The most recent example is a “*bona fide*” HFpEF murine model developed by the Hill Lab (Schiattarella et al., 2019), in which they described a defective unfolded protein response (UPR), which involves reduced inositol-requiring enzyme 1 alpha-X-box binding protein signaling that is not seen in other HFpEF models that only represent a transitional state between normal condition and HFrEF. Interestingly, Schiattarella et al. (2019) demonstrated defective relaxation properties at the cardiomyocyte level without a mechanism described in the same report. Based on our perspective introduced in this review, these cardiomyocytes may have (1) impaired Ca²⁺ handling system, (2) increased cell stiffness, or (3) prolonged myofibril relaxation. Potentially, with further investigation of both Ca²⁺ signaling of cardiomyocytes and mechanics of isolated myofibrils, researchers could determine which mechanisms are involved and develop a therapeutic strategy for HFpEF. If no abnormalities are observed at the level of the cardiomyocyte or the myofibril, the most likely contributor of diastolic dysfunction could be alterations in ECM such as altered ECM deposition or amyloid infiltration. With the advancement of technologies it is now feasible to specifically assess detailed ECM protein expression (Barallobre-Barreiro et al., 2016; Cui et al., 2019) and detailed stiffness/elastic properties of heart tissues (Borin et al., 2018), with experimental systems allowing for the analysis of cellular and myofibril mechanics (Lin et al., 2019; Sala et al., 2018).

There are many clinical trials targeting the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) to indirectly ameliorate heart function in HFrEF (Brann et al., 2019; Pellicori et al., 2020), but new therapeutic targets are necessary to directly improve diastolic function in HFpEF patients. It is important to focus on the detailed mechanisms leading to the diastolic dysfunction of the heart, including stiffness and active relaxation of the myocardium, cardiomyocyte, and myofibril. Current therapeutic approaches that ameliorate the stiffness of the myocardium have focused on targeting fibrosis and titin. Emerging fields such as tubulin detyrosination and filamin C also provide promising targets for further investigation. In contrast, treatments to improve muscle relaxation either through calcium handling or sarcomere function are mostly still preliminary, but have great potential

to unveil more targets for clinical application. Knowledge obtained from these studies could help in the identification of new targets and discovery of new therapeutic strategies to ameliorate diastolic function and improve clinical outcomes in patients with HFpEF.

Acknowledgments

Sang-Ging Ong is supported by National Institutes of Health grant R00 HL130416 and R01 HL148756. Chrishan Ramachandra is supported by the Singapore Ministry of Health's National Medical Research Council under its Open Fund-Young Individual Research Grant (NMRC/OFYIRG/0073/2018), the National Health Innovation Centre Singapore under its Innovation to Develop Grant (NHIC-I2S-1811007) and the SingHealth Duke-NUS Academic Medical Centre under its SingHealth Duke-NUS Academic Medicine Research Grant (AM/TP033/2020 [SRDUKAMR2033]). Derek Hausenloy is supported by the British Heart Foundation (CS/14/3/31002), the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Duke-National University Singapore Medical School, Singapore Ministry of Health's National Medical Research Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017) and Collaborative Centre Grant scheme (NMRC/CGAug16C006), and the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2016-T2-2-021). This article is based upon work from COST Action EU-CARDIOPROTECTION CA16225 supported by COST (European Cooperation in Science and Technology).

References

- Ablorh N-AD, Thomas DD (2015) Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy. *Biophys Rev* 7:63-76.
- Abraham TP, Jones M, Kazmierczak K, Liang H-Y, Pinheiro AC, Wagg CS, Lopaschuk GD, Szczesna-Cordary D (2009) Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. *Cardiovasc Res* 82:84-92.
- Akin BL, Hurley TD, Chen Z, Jones LR (2013) The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum. *J Biol Chem* 288:30181-30191.
- Alegre-Cebollada J, Kosuri P, Giganti D, Eckels E, Rivas-Pardo JA, Hamdani N, Warren CM, Solaro RJ, Linke WA, Fernández JM (2014) S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding. *Cell* 156:1235-1246.
- Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 63:1123-1133.
- Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. *Circ Res* 72:463-469.
- Aziz F, Luqman-Arafath T, Enweluzo C, Dutta S, Zaeem MJJocmr (2013) Diastolic heart failure: a concise review. *J Clin Med* 5:327-324.
- Backx PH, Gao W-D, Azan-Backx MD, Marban E (1995) The relationship between contractile force and intracellular $[Ca^{2+}]$ in intact rat cardiac trabeculae. *J Gen Physiol* 105:1-19.
- Baicu CF, Stroud JD, Livesay VA, Hapke E, Holder J, Spinale FG, Zile MR (2003) Changes in extracellular collagen matrix alter myocardial systolic performance. *Am J Physiol-Heart C* 284:H122-H132.
- Baker DL, Hashimoto K, Grupp IL, Ji Y, Reed T, Loukianov E, Grupp G, Bhagwat A, Hoit B, Walsh R (1998) Targeted overexpression of the sarcoplasmic reticulum Ca^{2+} -ATPase increases cardiac contractility in transgenic mouse hearts. *Circ Res* 83:1205-1214.
- Balderas-Villalobos J, Molina-Muñoz T, Mailloux-Salinas P, Bravo G, Carvajal K, Gómez-Viquez NL (2013) Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome. *Am J Physiol-Heart C* 305:H1344-H1353.
- Barallobre-Barreiro J, Lynch M, Yin X, Mayr M (2016) Systems biology—opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix. *Cardiovas Res* 112:626-636.
- Bassani J, Bassani RA, Bers DM (1994) Relaxation in rabbit and rat cardiac cells: species-dependent differences in cellular mechanisms. *J Physiol* 476:279-293.
- Bers DM (2002) Cardiac excitation–contraction coupling. *Nature* 415:198-205.
- Bers DM, Zhu Y (2010) *Excitation-Contraction Coupling and Cardiac Contractile Force*. Springer, Dordrecht.
- Bhupathi SS, Chalasani S, Rokey R (2011) Stiff heart syndrome. *Clin Med Res* 9:92-99.
- Bhupathy P, Babu GJ, Periasamy M (2007) Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca^{2+} ATPase. *J Mol Cell Cardiol* 42:903-911.
- Bielecka-Dabrowa A, Sakowicz A, Misztal M, von Haehling S, Ahmed A, Pietrucha T, Rysz J, Banach MJJoc (2016) Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. *Int J Cardiol* 221:1073-1080.
- Blinks J, Rüdel R, Taylor S (1978) Calcium transients in isolated amphibian skeletal muscle fibres: detection with aequorin. *J Physiol* 277:291-323.
- Borbély A, Falcao-Pires I, Van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, Van Der Velden J (2009) Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. *Circ Res* 104:780-786.
- Borbély A, Van Der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ (2005) Cardiomyocyte stiffness in diastolic heart failure. *Circulation* 111:774-781.
- Borin D, Pecorari I, Pena B, Sbaizero O (2018) Novel insights into cardiomyocytes provided by atomic force microscopy. *SeminCell Dev Biol* 73:4-12.
- Brann A, Tran H, Greenberg B (2019) Contemporary Approach to Treating Heart Failure. *Trends Cardiovasc Med* S1050-1738:30161-6.
- Bristow MR (2000). β -Adrenergic receptor blockade in chronic heart failure. *Circulation* 101:558-569.
- Brodehl A, Ferrier RA, Hamilton SJ, Greenway SC, Brundler MA, Yu W, Gibson WT, McKinnon ML, McGillivray B, Alvarez N (2016) Mutations in FLNC are associated with familial restrictive cardiomyopathy. *Hum Mutat* 37:269-279.
- Bujak M, Frangogiannis NG (2007) The role of TGF- β signaling in myocardial infarction and cardiac remodeling. *Cardiovasc Res* 74:184-195.
- Butler J, Braunwald E, Gheorghide M (2014) Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. *JAMA* 312:789-790.
- Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR (2012) Why are some amyloidoses systemic? Does hepatic “chaperoning at a distance” prevent cardiac deposition in a transgenic model of human senile systemic

- (transthyretin) amyloidosis? *The FASEB Journal* 26:2283-2293.
- Caporizzo MA, Chen CY, Bedi K, Margulies KB, Prosser BL (2020) Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium. *Circulation* 141:902-915.
- Chen CY, Caporizzo MA, Bedi K, Vite A, Bogush AI, Robison P, Heffler JG, Salomon AK, Kelly NA, Babu A (2018) Suppression of deetyrosinated microtubules improves cardiomyocyte function in human heart failure. *Nat Med* 24:1225-1233.
- Chen CY, Salomon AK, Caporizzo MA, Curry S, Kelly NA, Bedi KC, Bogush AI, Krämer E, Schlossarek S, Janiak P (2020) Depletion of Vasohibin 1 Speeds Contraction and Relaxation in Failing Human Cardiomyocytes. *Circ Res* <https://doi.org/10.1161/CIRCRESAHA.119.315947>.
- Cheng Y, Rao V, Tu A-y, Lindert S, Wang D, Oxenford L, McCulloch AD, McCammon JA, Regnier M (2015) Troponin I mutations R146G and R21C alter cardiac troponin function, contractile properties, and modulation by protein kinase A (PKA)-mediated phosphorylation. *J Biol Chem* 290:27749-27766.
- Chiang W, Greaser ML, Lyons GE (2000) Filamin isogene expression during mouse myogenesis. *Dev Dynam* 217:99-108.
- Chung CS, Granzier HL (2011) Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. *J Mol Cell Cardiol* 50:731-739.
- Chung J-H, Biesiadecki BJ, Ziolo MT, Davis JP, Janssen PM (2016) Myofilament calcium sensitivity: role in regulation of in vivo cardiac contraction and relaxation. *Front Physiol* 7:562.
- Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, Entman ML (2011) Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. *J Mol Cell Cardiol* 50:248-256.
- Colson BA, Locher MR, Bekyarova T, Patel JR, Fitzsimons DP, Irving TC, Moss RL (2010) Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development. *J Physiol* 588:981-993.
- Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A, Santini L, Bargelli V, Rotellini M, Bartolucci G (2017) Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy. *Circ Heart Fail* 10:e003565.
- Cui Y, Zheng Y, Liu X, Yan L, Fan X, Yong J, Hu Y, Dong J, Li Q, Wu X (2019) Single-cell transcriptome analysis maps the developmental track of the human heart *Cell Rep* 26:1934-1950. e1935.
- Dai Z, Aoki T, Fukumoto Y, Shimokawa H, JJC (2012) Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. *J Cardiol* 60:416-421.
- Dalkilic I, Schienda J, Thompson T, Kunkel L (2006) Loss of FilaminC (FLNc) results in severe defects in myogenesis and myotube structure. *Mol Cell Biol* 26:6522-6534.
- Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ (1999) Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. *Circulation* 100:2308-2311.
- Dosanjh A (2007) Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. *Transplant Proc* 39:2153-2156.
- Dubrey S, Hawkins P, Falk R (2011) Amyloid diseases of the heart: assessment, diagnosis, and referral. *Heart* 97:75-84.
- Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 14:591-602.
- Dvornikov AV, Smolin N, Zhang M, Martin JL, Robia SL, de Tombe PP (2016) Restrictive cardiomyopathy troponin I R145W mutation does not perturb myofilament length-dependent activation in human cardiac sarcomeres. *J Biol Chem* 291:21817-21828.
- Ebashi S, Kodama A, Ebashi F (1968) Troponin: 1. Preparation and physiological function. *J Biol Chem* 64:465-477.
- Echegaray K, Andreu I, Lazkano A, Villanueva I, Sáenz A, Elizalde MR, Echeverría T, López B, Garro A, González A, Zubillaga E, Solla I, Sanz I, González J, Elósegui-Artola A, Roca-Cusachs P, Díez J, Ravassa S, Querejeta R (2017) Role of myocardial collagen in severe aortic stenosis with preserved ejection fraction and symptoms of heart failure. *Rev Esp Cardiol* 70:832-840.
- Eisner D, Caldwell J, Trafford A (2013) Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later. *Circ Res* 113:958-961.
- Fabiato A, Fabiato F (1979) Calcium and cardiac excitation-contraction coupling. *Ann Rev Physiol* 41:473-484.
- Fernández-Ruiz I (2016) Gene therapy: No improvement in outcomes with gene therapy for heart failure. *Nat Rev Cardiol* 13:122-123.
- Friebel J, Weithauer A, Witkowski M, Rauch BH, Savvatis K, Dörner A, Tabaraie T, Kasner M, Moos V and Bösel D (2019) Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. *Eur Heart J* 40:3318-3332.
- Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL (2015) A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern Med* 175:996-1004.
- Gerdes A (2012) Cardiomyocyte ultrastructure. *Muscle: Fundamental Biology and Mechanisms of Disease*, edited by Hill J, Olson E. San Diego, CA: Academic: 47-55.
- Glezeva N, Baugh J (2014) Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. *Heart Fail Rev* 19(5): 681-694.
- Gomes AV, Liang J, Potter JD (2005) Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. *J Biol Chem* 280:30909-30915.
- Gómez J, Lorca R, Reguero JR, Morís C, Martín M, Tranche S, Alonso B, Iglesias S, Alvarez V, Díaz-Molina B (2017) Screening of the filamin C gene in a large cohort of hypertrophic cardiomyopathy patients. *Circulation Cardiovasc Gene* 10:e001584.
- González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J* 36:2585-2594.
- Gordon A, Homsher E, Regnier M (2000) Regulation of contraction in striated muscle. *Physiol Rev* 80:853-924.
- Granzier H, Labeit S (2002) Cardiac titin: an adjustable multi-functional spring. *J Physiol* 541:335-342.
- Granzier HL, Irving TC (1995) Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. *Biophys J* 68:1027-1044.
- Greenberg B (2017) Gene therapy for heart failure: time to go back to the drawing board. *Eur J Heart Fail* 19:1542-1544.

- Groban L, Lindsey S, Wang H, Lin MS, Kassik KA, Machado FS, Carter CS (2012) Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 × Brown Norway male rats. *Age* 34:831-843.
- Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA (2009) Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. *Biophys J* 97:825-834.
- Guo W, Bharmal SJ, Esbona K, Greaser ML (2010) Titin diversity—alternative splicing gone wild. *J Biomed Biotech* 2010(2):753675.
- Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H, Li S, Parrish AM (2012) RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. *Nat Med* 18:766.
- Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K (2008) Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. *J Card Fail* 14(5): 355-367.
- Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA (2013) Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. *Cardiovasc Res* 97:464-471.
- Hamdani N, Franssen C, Lourenço A, Falcão-Pires I, Fontoura D, Leite S, Plettig L, López B, Ottenheim CA, Becher PM (2013) Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. *Circ Heart Fail* 6:1239-1249.
- Hamdani N, Hervent A-S, Vandekerckhove L, Matheussen V, Demolder M, Baerts L, De Meester I, Linke WA, Paulus WJ, De Keulenaer GW (2014) Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. *Cardiovasc Res* 104:423-431.
- Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. *Eur J Heart Fail* 9:1146-1155.
- Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. *J Mol Cell Cardiol* 34:951-969.
- Hasenfuss G, Pieske B, Holubarsch C, Alpert NR, Just H (1993) Excitation-contraction coupling and contractile protein function in failing and nonfailing human myocardium. *Adv Exp Med Biol* 346:91-100.
- Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. *Nat Rev Mol Cell Biol* 7:589-600.
- Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, Labeit S, Granzier H (2009) PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. *Circ Res* 105:631-638.
- Hopf A-E, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S, Bongardt S, Röhl W, Drove F, Scheerer N (2018) Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by neuregulin-1. *Circ Res* 123:342-355.
- Houser SR, Piacentino III V, Weisser J (2000) Abnormalities of calcium cycling in the hypertrophied and failing heart. *J Mol Cell Cardiol* 32:1595-1607.
- Huang CL (2013) SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications. *Brit J Pharmacol* 170:486-488.
- Huxley AF (1957) Muscle structure and theories of contraction. *Prog. Biophys. Biophys. Chem* 7:255-318.
- Iorga B, Blaudeck N, Solzin J, Neulen A, Stehle I, Davila AJL, Pfitzer G, Stehle R (2008) Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils. *Cardiovasc Res* 77:676-686.
- Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date M-o, Chrast J, Matsuzaki M, Peterson KL (2004) Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. *J Clin Invest* 113:727-736.
- Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. *J Card Fail* 15:171-181.
- Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavinan MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB (2018) Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. *Sci Transl Med* 10:eaa0144.
- Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kühl U, Schultheiss H-P, Tschöpe CJ (2011) Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. *J Am Coll Cardiol* 57:977-985.
- Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee S-J (2017) Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. *J Clin Invest* 127:3770-3783.
- Kholova I, Niessen H (2005) Amyloid in the cardiovascular system: a review. *J Clin Path* 58:125-133.
- Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M (2017) Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. *Eur J Heart Fail* 19:1495-1503.
- Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. *J Am Coll Cardiol* 62:1330-1338.
- Kranstuber A, del Rio C, Biesiadecki B, Hamlin R, Ottobre J, Gyorke S, Lacombe VA (2012) Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. *Front Physiol* 3: 292.
- Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, Dos Remedios CG, Linke WA (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. *Circ Res* 104:87-94.
- Kruger M, Zitztrich S, Redwood C, Blaudeck N, James J, Robbins J, Pfitzer G, Stehle R (2005) Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-relaxation cycle in isolated cardiac myofibrils. *J Physiol* 564:347-357.
- Lam CS, Voors AA, De Boer RA, Solomon SD, Van Veldhuisen DJ (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. *Eur Heart J* 39:2780-2792.
- Leber Y, Ruparel AA, Kirfel G, van der Ven PF, Hoffmann B, Merkel R, Bryson-Richardson RJ, Fürst DO (2016) Filamin C is a highly dynamic protein associated with fast repair of myofibrillar microdamage. *Hum Mol Gene* 25:2776-2788.
- Lekavich CL, Barksdale DJ, Neelon V, Wu JR (2015) Heart failure preserved ejection fraction (HFpEF): an integrated

- and strategic review. *Heart Fail Rev* 20:643-653.
- LeWinter MM, Granzier H (2010) Cardiac titin: a multifunctional giant. *Circulation* 121:2137-2145.
- Lin Y-H, Yap J, Ramachandra CJ, Hausenloy DJ (2019) New insights provided by myofibril mechanics in inherited cardiomyopathies. *Cond Med* 2(5): 213-224.
- Lin YH, Schmidt W, Fritz KS, Jeong MY, Cammarato A, Foster DB, Biesiadecki BJ, McKinsey TA, Woulfe KC (2020) Site-specific acetyl-mimetic modification of cardiac troponin I modulates myofilament relaxation and calcium sensitivity. *J Mol Cell Cardiol* 139:135-147.
- Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroff RC (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *J Card Fail* 11:191-195.
- Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. *J Cell Mol Med* 13:1751-1764.
- MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. *Nat Rev Mol Cell Biol* 4:566-577.
- Marks AR (2013) Calcium cycling proteins and heart failure: mechanisms and therapeutics. *J Clin Invest* 123:46-52.
- Martos Rn, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald KJ (2007) CLINICAL PERSPECTIVE. *Circulation* 115:888-895.
- Maruyama K, Clarke DM, Fujii J, Loo TW, MacLennan DH (1989) Expression and mutation of Ca²⁺ ATPases of the sarcoplasmic reticulum. *Cell Motil Cytoskel* 14:26-34.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 371: 993-1004.
- Methawasin M, Strom JG, Slater RE, Fernandez V, Saripalli C, Granzier H (2016) Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. *Circulation* 134:1085-1099.
- Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats" *Brit J Pharmacol* 133:687-694.
- Mirkovic S, Seymour AML, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L (2002) Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. *Brit J Pharmacol* 135:961-968.
- Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, Gimeno JR, Elliott P, McKenna WJ (2003) Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *J Clin Invest* 111:209-216.
- Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC: Heart Fail* 2:113-122.
- Morgan JP (1991) Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. *N Engl J Med* 325:625-632.
- Morris DA, Otani K, Bekfani T, Takigiku K, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Friedrich K (2014). Multidirectional global left ventricular systolic function in normal subjects and patients with hypertension: multicenter evaluation. *J Am Soc Echocardiogr* 27:493-500.
- Moss RL, Fitzsimons DP, Ralphe JC (2015) Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium. *Circ Res* 116:183-192.
- Mouton AJ, Li X, Hall ME, Hall JE (2020) Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. *Circ Res* 126:789-806.
- Neague C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA (2002) Titin isoform switch in ischemic human heart disease. *Circulation* 106:1333-1341.
- Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ (1997) Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. *Circulation* 96:1991-1998.
- Nuss HB, Houser SR (1992) Sodium-calcium exchange-mediated contractions in feline ventricular myocytes. *A J Physiol Heart Circ Physiol* 263:H1161-H1169.
- Ou Q, Jacobson Z, Abouleisa RR, Tang X-L, Hindi SM, Kumar A, Ivey KN, Giridharan G, El-Baz A, Brittian K (2019) Physiological biomimetic culture system for pig and human heart slices. *Circ Res* 125:628-642.
- Pabel S, Wagner S, Bollenberg H, Bengel P, Kovacs A, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J (2018) Empagliflozin directly improves diastolic function in human heart failure. *Eur J Heart Fail* 20:1690-1700.
- Palano G, Jansson M, Backmark A, Martinsson S, Sabirsh A, Hultenby K, Åkerblad P, Granberg K, Jennbacken K, Müllers E (2020) A high-content, in vitro cardiac fibrosis assay for high-throughput, phenotypic identification of compounds with anti-fibrotic activity. *J Mol Cell Cardiol* 142:105-117.
- Park M, Sandner P, Krieg T (2018) cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. *Basic Res Cardiol* 113:24.
- Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 62:263-271.
- Pellicori P, Khan MJI, Graham FJ, Cleland JG (2020) New perspectives and future directions in the treatment of heart failure. *Heart Fail Rev* 25:147-159.
- Piazzino III V, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR (2003) Cellular basis of abnormal calcium transients of failing human ventricular myocytes. *Circ Res* 92:651-658.
- Pieske B, Maier LS, Bers DM, Hasenfuss G (1999) Ca²⁺ handling and sarcoplasmic reticulum Ca²⁺ content in isolated failing and nonfailing human myocardium. *Circ Res* 85:38-46.
- Pieske B, Tschöpe C, De Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CS (2019) How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J* 40:3297-3317.
- Pioner JM, Guan X, Klaiman JM, Racca AW, Pabon L, Muskheli V, Macadangang J, Ferrantini C, Hoopmann MR, Moritz RL (2020) Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells. *Cardiovasc Res* 116:368-382.
- Pioner JM, Racca AW, Klaiman JM, Yang K-C, Guan X, Pabon L, Muskheli V, Zaunbrecher R, Macadangang J, Jeong

- MY (2016) Isolation and mechanical measurements of myofibrils from human induced pluripotent stem cell-derived cardiomyocytes. *Stem Cell Rep* 6:885-896.
- Pislaru C, Ionescu F, Alashry M, Petrescu I, Pellikka PA, Grogan M, Dispenzieri A, Pislaru SV (2019) Myocardial stiffness by intrinsic cardiac elastography in patients with amyloidosis: comparison with chamber stiffness and global longitudinal strain. *J Am Soc Echocardiogr* 32:958-968.
- Plodinec M, Loparic M, Suetterlin R, Herrmann H, Aebi U, Schoenenberger C-A (2011) The nanomechanical properties of rat fibroblasts are modulated by interfering with the vimentin intermediate filament system. *J Struct Biol* 174:476-484.
- Poggesi C, Tesi C, Stehle R (2005) Sarcomeric determinants of striated muscle relaxation kinetics. *Pflügers Archiv* 449:505-517.
- Ponikowski P et al., (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 18(8):891-975.
- Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA* 309:1268-1277.
- Reil J-C, Hohl M, Reil G-H, Granzier HL, Kratz MT, Kazakov A, Fries P, Müller A, Lenski M, Custodis F (2013) Heart rate reduction by I f-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. *Eur Heart J* 34:2839-2849.
- Robinson JM, Wang Y, Kerrick WGL, Kawai R, Cheung HC (2002) Activation of striated muscle: nearest-neighbor regulatory-unit and cross-bridge influence on myofilament kinetics. *J Mol Biol* 322:1065-1088.
- Robinson TF, Factor SM, Sonnenblick EHJSA (1986) The heart as a suction pump. *Sci Am* 254:84-91.
- Robison P, Caporizzo MA, Ahmadzadeh H, Bogush AI, Chen CY, Margulies KB, Shenoy VB, Prosser BL (2016) Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. *Science* 352:aaf0659.
- Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. *New N Engl J Med* 372:1138-1149.
- Røe ÅT, Aronsen JM, Skårdal K, Hamdani N, Linke WA, Danielsen HE, Sejersted OM, Sjaastad I, Louch WEJCr (2017) Increased passive stiffness promotes diastolic dysfunction despite improved Ca²⁺ handling during left ventricular concentric hypertrophy. *Cardiovasc Res* 113:1161-1172.
- Roh J, Houstis N, Rosenzweig A (2017) Why don't we have proven treatments for HFpEF? *Circ Res* 120:1243-1245.
- Rommel K-P, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lücke C, Gutberlet M (2016) Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. *J Am Coll Cardiol* 67:1815-1825.
- Rosas PC, Liu Y, Abdalla MI, Thomas CM, Kidwell DT, Dusio GF, Mukhopadhyay D, Kumar R, Baker KM, Mitchell BM (2015) Phosphorylation of cardiac myosin-binding protein-C is a critical mediator of diastolic function. *Circ Heart Fail* 8:582-594.
- Rosas PC, Warren CM, Creed HA, Trzeciakowski JP, Solaro RJ, Tong CW (2019) Cardiac Myosin Binding Protein-C Phosphorylation Mitigates Age-Related Cardiac Dysfunction: Hope for Better Aging? *JACC: Basic Transl Sci* 4:817-830.
- Rouhana S, Farah C, Roy J, Finan A, de Araujo GR, Bideaux P, Scheuermann V, Saliba Y, Reboul C, Cazorla O (2019) Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction. *Biochim Biophys Acta (BBA)-Mol Basis Dis* 1865:230-242.
- Sala L, Van Meer BJ, Tertoolen LG, Bakkers J, Bellin M, Davis RP, Denning C, Dieben MA, Eschenhagen T, Giacomelli E (2018) MUSCLEMOTION: a versatile open software tool to quantify cardiomyocyte and cardiac muscle contraction in vitro and in vivo. *Circ Res* 122:e5-e16.
- Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, Luo X, Jiang N, May HI, Wang ZV (2019) Nitrosative stress drives heart failure with preserved ejection fraction. *Nature* 568:351-356.
- Schimmel K, Jung M, Foinquinos A, José GS, Beaumont J, Bock K, Grote-Levi L, Xiao K, Bär C, Pfanne A (2020) Natural compound library screening identifies new molecules for the treatment of cardiac fibrosis and diastolic dysfunction. *Circulation* 141:751-767.
- Schmidt U, Hajjar RJ, Kim CS, Lebeche D, Doye AA, Gwathmey JK (1999) Human heart failure: cAMP stimulation of SR Ca²⁺-ATPase activity and phosphorylation level of phospholamban. *Am J Physiol Heart Circ Physiol* 277:H474-H480.
- Scotcher J, Pryszazhna O, Boguslavskyi A, Kistamas K, Hadgraft N, Martin ED, Worthington J, Rudyk O, Cutillas PR, Cuello F (2016) Disulfide-activated protein kinase G I α regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response. *Nat Comm* 7:1-11.
- Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio AL, Farmakis D (2019) Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 21:553-576.
- Sevrieva IR, Brandmeier B, Ponnam S, Gautel M, Irving M, Campbell KS, Sun Y-B, Kampourakis T (2020) Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I. *J Biol Chem* 295:4398-4410.
- Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P (2009) Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. *Am Heart J* 157:1035-1041.
- Shah SJ, Kitzman DW, Borlaug BA, Van Heerebeek L, Zile MR, Kass DA, Paulus WJ (2016) Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. *Circulation* 134:73-90.
- Shaikh SA, Sahoo SK, Periasamy M (2016) Phospholamban and sarcolipin: are they functionally redundant or distinct regulators of the sarco (endo) plasmic reticulum calcium ATPase? *J Mol Cell Cardiol* 91:81-91.
- Slater RE, Strom JG, Granzier H (2017) Effect of exercise on passive myocardial stiffness in mice with diastolic dysfunction. *J Mol Cell Cardiol* 108:24-33.
- Slater RE, Strom JG, Methawasin M, Liss M, Gotthardt M, Sweitzer N, Granzier HL (2019) Metformin improves diastolic function in an HFpEF-like mouse model by

- increasing titin compliance. *J Gem Physiol* 151:42-52.
- Solaro RJ, Henze M, Kobayashi T (2013) Integration of troponin I phosphorylation with cardiac regulatory networks. *Circ Res* 112:355-366.
- Stehle R, Krüger M, Pfitzer G (2002) Force kinetics and individual sarcomere dynamics in cardiac myofibrils after rapid Ca^{2+} changes. *Biophysical J* 83:2152-2161.
- Stehle R, Solzin J, Iorga B, Poggesi C (2009) Insights into the kinetics of Ca^{2+} -regulated contraction and relaxation from myofibril studies. *Pflügers Archiv-Eur J of Physiol* 458:337-357.
- Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. *Circulation* 126:65-75.
- Stephens R, Edds K (1976) Microtubules: structure, chemistry, and function. *Physiol Rev* 56:709-777.
- Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, Shapiro SS (2001) Filamins as integrators of cell mechanics and signalling. *Nat Rev Mol Cell Biol* 2:138-145.
- Su M-YM, Lin L-Y, Tseng Y-HE, Chang C-C, Wu C-K, Lin J-L, Tseng W-YI (2014) CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. *JACC: Cardiovasc Imag* 7:991-997.
- Tada M, Toyofuku T (1996) SR Ca^{2+} -ATPase/phospholamban in cardiomyocyte function. *J Card Fail* 2:S77-S85.
- Tanaka K, Wilson RM, Essick EE, Duffen JL, Scherer PE, Ouchi N, Sam F (2014) Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. *Circ Heart Fail* 7:976-985.
- Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams Jr KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M (2016) Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. *The Lancet* 388:2895-2903.
- Tesi C, Piroddi N, Colomo F, Poggesi C (2002) Relaxation kinetics following sudden Ca^{2+} reduction in single myofibrils from skeletal muscle. *Biophys J* 83:2142-2151.
- Tracy LE, Minasian RA, Caterson E (2016) Extracellular matrix and dermal fibroblast function in the healing wound. *Adv in Wound Care* 5:119-136.
- van Heerebeek L, MD, Borbély A, Niessen HW, Bronzwaer JG, Van Der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ (2006) Myocardial structure and function differ in systolic and diastolic heart failure. *Circulation* 113:1966-1973.
- van Heerebeek L, Somsen A, Paulus WJ (2009) The failing diabetic heart: focus on diastolic left ventricular dysfunction. *Current diabetes reports* 9:79-86.
- Viner RI, Williams TD, Schöneich C (1999) Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue (s) in the sarcoplasmic reticulum Ca-ATPase. *Biochem* 38:12408-12415.
- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN (2020) Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation* 141:e139.
- Wallner M, Eaton DM, Berretta RM, Liesinger L, Schittmayer M, Gindlhuber J, Wu J, Jeong MY, Lin YH, Borghetti G et al. (2020) HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. *Sci Transl Med* 12:eaay7205.
- Warren CM, Krzesinski PR, Campbell KS, Moss RL, Greaser ML (2004) Titin isoform changes in rat myocardium during development. *Mech Dev* 121:1301-1312.
- Weber A, Murray JM (1973) Molecular control mechanisms in muscle contraction. *Physiol Rev* 53:612-673.
- Wilder T, Ryba DM, Wieczorek DF, Wolska BM, Solaro RJ (2015) N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. *Am J Physiol Heart Circ Physiol* 309:H1720-H1730.
- Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, Schalkwijk C, van der Horst IC, Hillege HL, Voors AA (2012) The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. *Am Heart J* 164:742-749. e743.
- Wu H, Yang H, Rhee J-W, Zhang JZ, Lam CK, Sallam K, Chang AC, Ma N, Lee J, Zhang H (2019) Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. *Eur Heart J* 40:3685-3695.
- Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H (2002) Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. *Circulation* 106:1384-1389.
- Xie M, Huang H-L, Zhang W-H, Gao L, Wang Y-W, Zhu X-J, Li W, Chen K-S, Boutjdir M, Chen L (2020) Increased sarcoplasmic/endoplasmic reticulum calcium ATPase 2a activity underlies the mechanism of the positive inotropic effect of ivabradine. *Exp Physiol* 105:477-488.
- Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara TJC (2002) Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. *Cardiovasc Res* 55:76-82.
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol* 70:776-803.
- Yuan C-C, Kazmierczak K, Liang J, Kanashiro-Takeuchi R, Irving TC, Gomes AV, Wang Y, Burghardt TP, Szczesna-Cordary D (2017) Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice. *Cardiovasc Res* 113:1124-1136.
- Zarain-Herzberg A, García-Rivas G, Estrada-Avilés R (2014) Regulation of SERCA pumps expression in diabetes. *Cell Calcium* 56:302-310.
- Zhai Y, Luo Y, Wu P, Li D (2018) New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides. *J Med Gene* 55:287-296.
- Zhang R, Zhao J, Mandveno A, Potter JD (1995) Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. *Circ Res* 76:1028-1035.
- Ziaiean B, Fonarow GC (2016) Epidemiology and aetiology of heart failure. *Nat Rev Cardiol* 13:368-378.
- Zile MR, Baicu CF, S. Ikonomidis J, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M (2015) Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. *Circulation* 131:1247-1259.
- Zima AV, Blatter LA (2006) Redox regulation of cardiac calcium channels and transporters. *Cardiovasc Res* 71:310-321.